Jenburkt Pharmaceuticals Peer Comparison

Jenburkt Pharmaceuticals Ltd. is currently undervalued with a low PE ratio and zero debt, but faces challenges in growth and profitability. Among its peers, it stands out as a potential value pick, despite having no growth metrics to show. Companies like Sun Pharmaceutical and Mankind Pharma exhibit strong profitability but are relatively overvalued, indicating an opportunity for investors to consider Jenburkt as a contrarian play.

• • Jenburkt Pharmaceuticals has a low PE of 15.67 and zero debt, making it attractive from a valuation perspective.
• • The company lacks growth metrics, showing 0% revenue and EPS growth year-over-year and over three years.
• • Sun Pharmaceutical Industries and Mankind Pharma show strong profitability but are at higher valuation ratios, indicating potential overvaluation.

• • Sun Pharmaceutical Industries Ltd.: Highest revenue growth YoY at 8.42% and strong profitability metrics.
• • Mankind Pharma Ltd.: Strongest revenue growth of 18.12% YoY and high ROE of 23.15%.
• • Dr. Reddy's Laboratories Ltd.: High ROE at 21.76% and solid growth with 16.54% revenue increase YoY.